KESIMPTA was studied in 2 head-to-head studies vs AUBAGIO® (teriflunomide). Few people stopped treatment due to side effects: comparable to AUBAGIO: 5.7% for KESIMPTA, 5.2% for AUBAGIO. Mild to moderate injection-related reactions: 99.8% of injection-related reactions were mild to moderate. They were most common in the first injection and …
The World Web Times - worldwebtimes.comThe World Web Times - worldwebtimes.com - The News And Times | Israel And The Middle East
